P. Fargeot

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial

Jacques Bonneterre, Henri Roché, Pierre Kerbrat et al. · Journal of Clinical Oncology · 2005 · 274 citations · Full text

Medicine, Oncology, Pharmacology +17

Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial

Laura Biganzoli, Tanja Čufer, P.F. Bruning et al. · Journal of Clinical Oncology · 2002 · 220 citations

Medicine, Oncology, Pharmacology +17

Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Trials of Adjuvant Epirubicin for Early Breast Cancer: Correlation With Doses of Epirubicin and Cyclophosphamide

C Praga, Jonas Bergh, Judith M. Bliss et al. · Journal of Clinical Oncology · 2005 · 183 citations · Full text

Medicine, Oncology, Pharmacology +17

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer

Fabio Efficace, Laura Biganzoli, Martine Piccart et al. · European Journal of Cancer · 2004 · 162 citations

Medicine, Oncology, Breast Oncology +15

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Aude Fléchon, Damien Pouessel, Céline Ferlay et al. · Annals of Oncology · 2011 · 143 citations · Full text

Medicine, Oncology, Pharmacology +17